Janssen persuades Scotland to reimburse Zytiga
This article was originally published in Scrip
Janssen has managed to convince the Scottish Medicines Consortium, Scotland's health technology appraisal body, that the benefits of its anticancer Zytiga (abiraterone) do in fact justify the cost. The consortium has this week accepted the drug for use on the Scottish NHS for patients with metastatic castration resistant prostate cancer.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.